> ## Content Index
> Fetch the complete content index at: https://morpheus-research-labs.ghost.io/llms.txt
> Use this file to discover other available public pages before exploring further.

# Tesamorelin Research: The Stabilised GHRH Analogue and What Its Published Trials Measured
- URL: https://morpheus-research-labs.ghost.io/tesamorelin-research/
- Published: 2026-11-13T15:13:18.000Z
- Updated: 2026-11-13T15:13:17.000Z
- Description: Tesamorelin research explained: how a modified GHRH(1-44) resists DPP-4 cleavage, what its published trials measured, and the limits of that evidence for labs.
- Author: Morpheus Research
- Tags: Tesamorelin, Growth Hormone Secretagogues, Peptide Research

Tesamorelin is one of the few research peptides with a long, well-documented trail of controlled studies behind it. It is a synthetic analogue of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that signals the pituitary to release growth hormone. This article covers where GHRH came from, why the native hormone is a poor research tool on its own, what chemical change makes tesamorelin different, and what its published trials did and did not measure. It is written for laboratory researchers and makes no recommendation about human use.

## Where GHRH came from

The story starts with tumours. In 1982, two groups working independently isolated a growth hormone-releasing factor from human pancreatic tumours that had caused acromegaly, a condition of excess growth hormone. Guillemin and colleagues reported a 44-residue peptide in *Science*, and Rivier, Spiess, Thorner and colleagues reported their characterisation in *Nature* the same month. Esch and colleagues described a related 40-residue form in *Biochemical and Biophysical Research Communications*, and Brazeau and colleagues showed in *PNAS* that the factor released pituitary growth hormone in vitro.

The full hormone is GHRH(1-44)-NH2, a C-terminally amidated peptide. Later work showed that the first 29 residues carry most of the biological activity, which is why shorter fragments such as GHRH(1-29) became common research tools.

## Why native GHRH is hard to work with

Native GHRH is cleared and inactivated quickly. Frohman and colleagues studied this directly in the *Journal of Clinical Investigation* in 1986\. When they incubated GHRH(1-44)-NH2 with human plasma, total GHRH immunoreactivity had a half-life of 63 minutes by radioimmunoassay, but HPLC showed the intact peptide disappearing much faster, with a half-life of 17 minutes. The intact peptide was being converted into a product cleaved at the N-terminus, and that product was biologically inactive.

The enzyme responsible is dipeptidyl peptidase-4 (DPP-4), which removes the first two residues (tyrosine and alanine) from peptides that have alanine or proline at position two. The resulting GHRH(3-44) fragment still reacts with many antibodies but no longer activates the receptor well. This is a useful general lesson for anyone reading peptide data: an immunoassay can report "peptide present" long after the active form is gone. For more on this theme, see our overview of [peptide half-life extension strategies](https://morpheus-research-labs.ghost.io/peptide-half-life-extension-strategies/).

## What makes tesamorelin different

Tesamorelin (development code TH9507) keeps the full 44-amino-acid GHRH sequence and adds a trans-3-hexenoyl group to the N-terminal tyrosine. The modification sits exactly where DPP-4 acts. Capping the N-terminus in this way is intended to make the peptide a poorer substrate for that enzyme, so that the intact, active form survives longer in plasma, while the rest of the sequence still binds the GHRH receptor.

This is a good example of a targeted, minimal modification. Rather than redesigning the peptide, the developers blocked one known degradation route. It contrasts with other approaches to the same problem, such as the albumin-binding strategy used for CJC-1295 with DAC, which we discuss in our [CJC-1295 and ipamorelin overview](https://morpheus-research-labs.ghost.io/cjc-1295-ipamorelin-research/).

## How tesamorelin differs from ghrelin-receptor peptides

Tesamorelin is often mentioned alongside peptides such as ipamorelin and GHRP-6\. They are not the same class. Tesamorelin acts on the GHRH receptor, a class B G protein-coupled receptor on pituitary somatotrophs. Ipamorelin and GHRP-6 act on the growth hormone secretagogue receptor (GHS-R1a), the ghrelin receptor, which signals through a different pathway. Both routes can raise growth hormone release, but the upstream biology, the feedback involved and the experimental controls needed are different. Our article on [GHRP-6 research](https://morpheus-research-labs.ghost.io/ghrp-6-peptide-research/) covers the ghrelin-receptor side.

For study design, this matters. A shared downstream marker such as IGF-I does not make two compounds interchangeable, and results from one class cannot simply be transferred to the other.

## What the published trials measured

Tesamorelin's clinical literature focuses on one specific population: people with HIV who had accumulated abdominal fat during antiretroviral therapy. That narrow focus is important when reading the results.

**The first phase 3 trial (2007).** Falutz and colleagues reported in the *New England Journal of Medicine* a randomised, placebo-controlled trial in 412 patients with HIV and abdominal fat accumulation, 86% of whom were men. The primary endpoint was the percent change in visceral adipose tissue measured by computed tomography over 26 weeks. The authors reported a 15.2% decrease in the tesamorelin group and a 5.0% increase in the placebo group. IGF-I rose by 81.0% with tesamorelin and fell by 5.0% with placebo. Triglycerides and the total-to-HDL cholesterol ratio also improved. Adverse events did not differ significantly between groups overall, but more participants in the tesamorelin group withdrew because of an adverse event.

**Pooled phase 3 data (2010).** Falutz and colleagues later reported a pooled analysis of two multicentre phase 3 trials, with safety extension data, in the *Journal of Clinical Endocrinology and Metabolism*. A separate report of one of these trials with its extension appeared in the *Journal of Acquired Immune Deficiency Syndromes* the same year.

**Liver fat (2014).** Stanley and colleagues reported in *JAMA* a smaller randomised trial of 50 participants at Massachusetts General Hospital, with visceral fat and liver fat as primary endpoints over six months. Visceral fat fell compared with placebo, and liver fat showed what the authors called modest reductions. Fasting glucose rose in the tesamorelin group at two weeks, but the changes at six months were not significant. The authors described the study as preliminary.

**Non-alcoholic fatty liver disease (2019).** Stanley and colleagues followed this with a 12-month randomised, double-blind trial in people with HIV and a hepatic fat fraction of 5% or more, reported in *Lancet HIV*. Sixty-one people were enrolled. The authors reported an absolute reduction in hepatic fat fraction of 4.1 percentage points compared with placebo, a 37% relative reduction from baseline. Fasting glucose and glycated haemoglobin did not differ between groups at 12 months. Injection-site complaints were more common with tesamorelin. The authors called for further studies of long-term effects on liver histology.

Tesamorelin was approved by the US FDA in 2010 for a single, narrow indication in this HIV population. That approval applies to a specific manufactured medicine, not to research-grade material sold under the same name.

## Reading this evidence carefully

A few points keep this literature in proportion:

- **The population is narrow.** Nearly all controlled data come from people with HIV on antiretroviral therapy with abdominal fat accumulation. Results in that group cannot be assumed to apply elsewhere.
- **Imaging endpoints are surrogates.** Changes in visceral fat area or hepatic fat fraction are measurements, not proof of long-term outcomes. The trial authors themselves called for longer studies.
- **IGF-I is a marker, not an outcome.** A large rise in IGF-I shows the axis responded. It says nothing on its own about benefit or risk.
- **The material matters.** The trials used a pharmaceutical product with full manufacturing controls. Identity, purity and peptide content of research material must be checked independently, for example with HPLC and mass spectrometry. See our guide to [reading a peptide COA](https://morpheus-research-labs.ghost.io/peptide-coa-explained/).

## Research questions tesamorelin is suited to

For laboratory work, tesamorelin is most useful as a tool for studying the GHRH receptor and the effect of N-terminal protection on peptide stability. Typical questions include comparing intact-peptide survival of native GHRH and tesamorelin in plasma or serum by LC-MS, mapping which fragments form over time, and comparing GHRH-receptor and ghrelin-receptor signalling in cell systems. Recent analytical work has also focused on detecting tesamorelin and its metabolites by high-resolution mass spectrometry, a reminder that metabolite identification is an active research area in its own right.

## Frequently asked questions

**Is tesamorelin the same as GHRH?** No. It has the same 44-residue sequence as human GHRH(1-44) but adds a trans-3-hexenoyl group to the N-terminal tyrosine.

**Is tesamorelin a ghrelin-receptor peptide like ipamorelin?** No. Tesamorelin acts on the GHRH receptor. Ipamorelin and GHRP-6 act on the ghrelin receptor.

**Why does the N-terminal modification matter?** Native GHRH is rapidly cut at its N-terminus by DPP-4 into an inactive fragment. The modification sits at that cleavage site.

## Related reading

- [Peptide Half-Life Extension Strategies](https://morpheus-research-labs.ghost.io/peptide-half-life-extension-strategies/)
- [GHRP-6 Research](https://morpheus-research-labs.ghost.io/ghrp-6-peptide-research/)
- [CJC-1295 and Ipamorelin Research](https://morpheus-research-labs.ghost.io/cjc-1295-ipamorelin-research/)
- [Receptor Binding Assays Explained](https://morpheus-research-labs.ghost.io/receptor-binding-assays-explained/)

## References

- Guillemin R, Brazeau P, Böhlen P, et al. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. *Science.* 1982;218(4572):585-587\. doi:10.1126/science.6812220.
- Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. *Nature.* 1982;300(5889):276-278\. doi:10.1038/300276a0.
- Esch FS, Böhlen P, Ling NC, et al. Characterization of a 40 residue peptide from a human pancreatic tumor with growth hormone releasing activity. *Biochemical and Biophysical Research Communications.* 1982;109(1):152-158\. doi:10.1016/0006-291x(82)91578-9.
- Brazeau P, Ling N, Böhlen P, et al. Growth hormone releasing factor, somatocrinin, releases pituitary growth hormone in vitro. *PNAS.* 1982;79(24):7909-7913\. doi:10.1073/pnas.79.24.7909.
- Frohman LA, Downs TR, Williams TC, et al. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. *Journal of Clinical Investigation.* 1986;78(4):906-913\. doi:10.1172/JCI112679.
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. *New England Journal of Medicine.* 2007;357(23):2359-2370\. doi:10.1056/NEJMoa072375.
- Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. *Journal of Acquired Immune Deficiency Syndromes.* 2010;53(3):311-322\. doi:10.1097/QAI.0b013e3181cbdaff.
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. *Journal of Clinical Endocrinology and Metabolism.* 2010;95(9):4291-4304\. doi:10.1210/jc.2010-0490.
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. *JAMA.* 2014;312(4):380-389\. doi:10.1001/jama.2014.8334.
- Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. *Lancet HIV.* 2019;6(12):e821-e830\. doi:10.1016/S2352-3018(19)30338-8.
- Colpaert T, Miller G, Goodrum J, et al. Detecting GHRH analogue tesamorelin and its metabolites in post-administration human urine and serum using LC-HRMS/MS. *Drug Testing and Analysis.* 2026\. doi:10.1002/dta.70189.

---

*Research use only. All products sold by Morpheus Research are intended strictly for laboratory research and are not for human or veterinary consumption. Nothing in this article is medical advice, and no statement here is intended to diagnose, treat, cure or prevent any condition. Study findings are reported as published and should not be read as evidence of effects in people.*